{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:15:59Z","timestamp":1762254959379,"version":"3.40.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pharma.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T16:18:34Z","timestamp":1723133914000},"page":"994-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aqueous eye drop formulations: Cyclodextrins as enabling excipients"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1589-967X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Pilotaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-1553","authenticated-orcid":false,"given":"Thorsteinn","family":"Loftsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3311\/PPch.21222","article-title":"Recent list of cyclodextrin-containing drug products","volume":"67","author":"Pusk\u00e1s","year":"2023","journal-title":"Periodica Polytechnica-Chem Eng"},{"issue":"4","key":"10.1016\/j.pharma.2024.08.003_bib0295","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1097-0029(19960301)33:4<320::AID-JEMT3>3.0.CO;2-T","article-title":"Ultrastructure of the human cornea","volume":"33","author":"Beuerman","year":"1996","journal-title":"Microsc Res Techn"},{"issue":"12","key":"10.1016\/j.pharma.2024.08.003_bib0300","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J Pharm Sci"},{"issue":"9\u201310","key":"10.1016\/j.pharma.2024.08.003_bib0305","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/10611860400015910","article-title":"Cationic vectors in ocular drug delivery","volume":"12","author":"Rabinovich-Guilatt","year":"2004","journal-title":"J Drug Targeting"},{"issue":"4","key":"10.1016\/j.pharma.2024.08.003_bib0310","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/(SICI)1097-0029(19960301)33:4<296::AID-JEMT2>3.0.CO;2-O","article-title":"Conjunctiva","volume":"33","author":"Nichols","year":"1996","journal-title":"Microsc Res Techn"},{"issue":"9","key":"10.1016\/j.pharma.2024.08.003_bib0315","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.xphs.2017.04.061","article-title":"Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of In Silico model","volume":"106","author":"Ramsay","year":"2017","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharma.2024.08.003_bib0320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050658","article-title":"Partitioning and spatial distribution of drugs in ocular surface tissues","volume":"13","author":"Balla","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharma.2024.08.003_bib0325","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2\u20133","key":"10.1016\/j.pharma.2024.08.003_bib0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-3659(97)00078-3","article-title":"Estimation of pore size and pore density of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach","volume":"49","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"J Controlled Release"},{"issue":"3","key":"10.1016\/j.pharma.2024.08.003_bib0335","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II tear film report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.pharma.2024.08.003_bib0340","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejpb.2015.02.032","article-title":"Undefined role of mucus as a barrier in ocular drug delivery","volume":"96","author":"Ruponen","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.pharma.2024.08.003_bib0345","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10847-006-9253-4","article-title":"Dexamethasone delivery to posterior segment of the eye","volume":"57","author":"Loftsson","year":"2007","journal-title":"J Incl Phenom Macroc Chem"},{"issue":"11","key":"10.1016\/j.pharma.2024.08.003_bib0350","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.pharma.2024.08.003_bib0355","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040452","article-title":"Biopharmaceutics of topical ophthalmic suspensions: importance of viscosity and particle size in ocular absorption of indomethacin","volume":"13","author":"Toropainen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharma.2024.08.003_bib0360","doi-asserted-by":"crossref","first-page":"954771","DOI":"10.3389\/fddev.2022.954771","article-title":"Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye?","volume":"2","author":"del Amo","year":"2022","journal-title":"Front Drug Deliv"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425247.2022.2017878","article-title":"Topical drug delivery to the retina: obstacles and routes to success","volume":"19","author":"Loftsson","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0370","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10010010","article-title":"Ophthalmic drug delivery systems for antibiotherapy\u00a0\u2013\u00a0a review","volume":"10","author":"Dubald","year":"2018","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharma.2024.08.003_bib0375","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-01977-0","article-title":"Review of Approaches for increasing ophthalmic bioavailability for eye drop formulations","volume":"22","author":"Lanier","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.pharma.2024.08.003_bib0380","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.carres.2005.11.004","article-title":"Solubility of cyclomaltooligosaccharides (cyclodextrins) in H2O and D2O: a comparative study","volume":"341","author":"Sabadini","year":"2006","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.pharma.2024.08.003_bib0385","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.02.004","article-title":"Self-association of cyclodextrins and cyclodextrin complexes in aqueous solutions","volume":"560","author":"Loftsson","year":"2019","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0390","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharma.2024.08.003_bib0400","series-title":"Advances in analytical chemistry and instrumentation","first-page":"117","article-title":"Phase-solubility techniques","author":"Higuchi","year":"1965"},{"issue":"2","key":"10.1016\/j.pharma.2024.08.003_bib0405","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijpharm.2017.05.024","article-title":"Soluble 1:1 complexes and insoluble 3:2 complexes\u00a0\u2013\u00a0Understanding the phase-solubility diagram of hydrocortisone and \u03b3-cyclodextrin","volume":"531","author":"Sch\u00f6nbeck","year":"2017","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.pharma.2024.08.003_bib0410","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3390\/molecules23051204","article-title":"Characterization of cyclodextrin\/volatile inclusion complexes: a review","volume":"23","author":"Kfoury","year":"2018","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.pharma.2024.08.003_bib0415","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/ma16062223","article-title":"Anomalous properties of cyclodextrins and their complexes in aqueous solutions","volume":"16","author":"Loftsson","year":"2023","journal-title":"Materials"},{"key":"10.1016\/j.pharma.2024.08.003_bib0420","first-page":"597","article-title":"Topical drug delivery to the posterior segment of the eye: thermodynamic considerations","author":"Sripetch","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2024.08.003_bib0425","series-title":"Cyclodextrins: synthesis, chemical applications and role in drug delivery","first-page":"293","article-title":"Sulfobutylether-cyclodextrins: structure, degree of substitution and functional performance","author":"Pusk\u00e1s","year":"2015"},{"issue":"3","key":"10.1016\/j.pharma.2024.08.003_bib0430","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00126839-200203030-00001","article-title":"A comparison of two different formulations of diclofenac sodium 0.1% in the treatment of inflammation following cataract-intraocular lens surgery","volume":"3","author":"Mester","year":"2002","journal-title":"Drugs R&D"},{"key":"10.1016\/j.pharma.2024.08.003_bib0435","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5260976","article-title":"Cyclodextrin enhances corneal tolerability and reduces ocular toxicity caused by diclofenac","author":"Abdelkader","year":"2018","journal-title":"Oxid Med Cell Longevity"},{"issue":"2","key":"10.1016\/j.pharma.2024.08.003_bib0440","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijpharm.2017.06.009","article-title":"Effects of cyclodextrins on the chemical stability of drugs","volume":"531","author":"Popielec","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2024.08.003_bib0445","doi-asserted-by":"crossref","first-page":"214919","DOI":"10.1016\/j.ccr.2022.214919","article-title":"Cyclodextrin-based ocular drug delivery systems: a comprehensive review","volume":"476","author":"Wang","year":"2023","journal-title":"Coord Chem Rev"},{"issue":"2","key":"10.1016\/j.pharma.2024.08.003_bib0450","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.pharma.2024.08.003_bib0455","series-title":"Nanotools for the treatment of ocular diseases","first-page":"169","author":"Campos","year":"2022"},{"key":"10.1016\/j.pharma.2024.08.003_bib0460","doi-asserted-by":"crossref","first-page":"112212","DOI":"10.1016\/j.msec.2021.112212","article-title":"Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases","volume":"127","author":"Fang","year":"2021","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.pharma.2024.08.003_bib0465","first-page":"121654","article-title":"Self-assembled \u03b3-cyclodextrin as nanocarriers for enhanced ocular drug bioavailability","volume":"618","author":"Jansook","year":"2022","journal-title":"Int J Pharm (Amsterdam, Neth)"},{"key":"10.1016\/j.pharma.2024.08.003_bib0470","doi-asserted-by":"crossref","first-page":"104281","DOI":"10.1016\/j.jddst.2023.104281","article-title":"Topical dexamethasone delivery to the retina: an aqueous cyclodextrin-based microsuspension","volume":"81","author":"Loftsson","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.pharma.2024.08.003_bib0475","first-page":"120707","article-title":"Age-related ocular conditions: current treatments and role of cyclodextrin-based nanotherapies","volume":"603","author":"Lorenzo-Veiga","year":"2021","journal-title":"Int J Pharm (Amsterdam, Neth)"},{"issue":"Part_B","key":"10.1016\/j.pharma.2024.08.003_bib0480","doi-asserted-by":"crossref","first-page":"120347","DOI":"10.1016\/j.carbpol.2022.120347","article-title":"Sulfobutylether-\u03b2-cyclodextrin: a functional biopolymer for drug delivery applications","volume":"301","author":"Pardeshi","year":"2023","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.pharma.2024.08.003_bib0485","doi-asserted-by":"crossref","first-page":"105830","DOI":"10.1016\/j.reactfunctpolym.2024.105830","article-title":"Novel super porous nanosponge-based drug delivery system synthesized from cyclodextrin\/polymer for anti-fungal medication","volume":"196","author":"Sengupta","year":"2024","journal-title":"React Funct Polym"},{"issue":"Part_3","key":"10.1016\/j.pharma.2024.08.003_bib0490","doi-asserted-by":"crossref","first-page":"124902","DOI":"10.1016\/j.ijbiomac.2023.124902","article-title":"A review on carbohydrate polymer-based bioadhesive formulations and their potentials for the treatment of ocular diseases","volume":"242","author":"Tang","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0495","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1039\/D3TB02101G","article-title":"Engineered cyclodextrin-based supramolecular hydrogels for biomedical applications","volume":"12","author":"Zhao","year":"2024","journal-title":"J Mater Chem B"},{"issue":"5","key":"10.1016\/j.pharma.2024.08.003_bib0500","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.5812\/jjm.6333","article-title":"Problems in ophthalmic drug delivery: evaluation of the interaction between preservatives and cyclodextrins","volume":"6","author":"Malaekeh-Nikouei","year":"2013","journal-title":"Jundishapur J Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2024.08.003_bib0505","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0378-5173(99)00393-2","article-title":"Interaction of p-hydroxybenzoic esters with beta-cyclodextrin","volume":"195","author":"Chan","year":"2000","journal-title":"Int J Pharm"},{"issue":"13","key":"10.1016\/j.pharma.2024.08.003_bib0510","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3109\/03639049209040853","article-title":"Interactions between preservatives and 2-hydroxypropyl-\u03b2-cyclodextrin","volume":"18","author":"Loftsson","year":"1992","journal-title":"Drug Development and Industrial Pharmacy"},{"key":"10.1016\/j.pharma.2024.08.003_bib0515","series-title":"Cyclodextrins in pharmaceutics, cosmetics, and biomedicine: current and future industrial applications","first-page":"91","article-title":"Recent findings on safety profiles of cyclodextrins, cyclodextrin conjugates, and polypseudorotaxanes","author":"Arima","year":"2011"},{"key":"10.1016\/j.pharma.2024.08.003_bib0520","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.reprotox.2015.05.010","article-title":"Juvenile animal testing of hydroxypropyl-beta-cyclodextrin in support of pediatric drug development","volume":"56","author":"De Schaepdrijver","year":"2015","journal-title":"Reprod Toxicol"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0525","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.pharma.2024.08.003_bib0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2016.10.062","article-title":"\u03b3-Cyclodextrin","volume":"516","author":"Saokham","year":"2017","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.pharma.2024.08.003_bib0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","article-title":"Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation","volume":"86","author":"Irie","year":"1997","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.pharma.2024.08.003_bib0540","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/jphp.12427","article-title":"Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug\/cyclodextrin complexes","volume":"68","author":"Loftsson","year":"2016","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.12917","article-title":"Cyclodextrin-based formulations: a non-invasive platform for targeted drug delivery","volume":"122","author":"Muankaew","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.pharma.2024.08.003_bib0550","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/biom11091384","article-title":"Cyclodextrins as anti-inflammatory agents: basis, drugs and perspectives","volume":"11","author":"Lucia Appleton","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.pharma.2024.08.003_bib0555","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/aos.15215","article-title":"Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study","volume":"101","author":"Stefansson","year":"2023","journal-title":"Acta Ophthalmol"},{"year":"2023","series-title":"Multidose ophthalmic compositions, Patent application: WO2023148231","author":"Loftsson","key":"10.1016\/j.pharma.2024.08.003_bib0560"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092400110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092400110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:48:37Z","timestamp":1729705717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345092400110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S000345092400110X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.08.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aqueous eye drop formulations: Cyclodextrins as enabling excipients","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}